Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Yohan | - |
dc.date.accessioned | 2022-07-09T14:50:56Z | - |
dc.date.available | 2022-07-09T14:50:56Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/147728 | - |
dc.description.abstract | After the fist research declaring the generation of human induced pluripotent stem cells (hiPSCs) in 2007, several attempts have been made to model neurodegenerative disease in vitro during the past decade. Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is mainly characterized by motor dysfunction. The formation of unique and filamentous inclusion bodies called Lewy bodies (LBs) is the hallmark of both PD and dementia with LBs. The key pathology in PD is generally considered to be the alpha-synuclein (alpha-syn) accumulation, although it is still controversial whether this protein aggregation is a cause or consequence of neurodegeneration. In the present work, the recently published researches which recapitulated the alpha-syn aggregation phenomena in sporadic and familial PD hiPSC models were reviewed. Furthermore, the advantages and potentials of using patient-derived PD hiPSC with focus on alpha-syn aggregation have been discussed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.title | Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Yohan | - |
dc.identifier.doi | 10.5483/BMBRep.2019.52.6.142 | - |
dc.identifier.scopusid | 2-s2.0-85068972490 | - |
dc.identifier.wosid | 000473211900001 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.52, no.6, pp.349 - 359 | - |
dc.relation.isPartOf | BMB REPORTS | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 52 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 349 | - |
dc.citation.endPage | 359 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002475731 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | FOREBRAIN CHOLINERGIC NEURONS | - |
dc.subject.keywordPlus | MIDBRAIN DOPAMINE NEURONS | - |
dc.subject.keywordPlus | GLUCOCEREBROSIDASE MUTATIONS | - |
dc.subject.keywordPlus | HUMAN ES | - |
dc.subject.keywordPlus | GAUCHER-DISEASE | - |
dc.subject.keywordPlus | ANIMAL-MODELS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | PHOSPHORYLATION | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordAuthor | Aggregation | - |
dc.subject.keywordAuthor | Alpha-synuclein | - |
dc.subject.keywordAuthor | Disease modeling | - |
dc.subject.keywordAuthor | hiPSC | - |
dc.subject.keywordAuthor | Parkinson&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.identifier.url | https://www.bmbreports.org/journal/view.html?doi=10.5483/BMBRep.2019.52.6.142 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.